---
title: Lung cancer metabolomic data from tumor core biopsies enables risk-score calculation
  for progression-free and overall survival
date: '2022-05-14'
linkTitle: http://link.springer.com/10.1007/s11306-022-01891-x
source: Latest Results for Metabolomics
description: ' <h3 class="a-plus-plus">Abstract</h3> <span class="a-plus-plus abstract-section
  id-a-sec1"> <h3 class="a-plus-plus">Introduction</h3> <p class="a-plus-plus">Metabolomics
  has emerged as a powerful method to provide insight into cancer progression, including
  separating patients into low- and high-risk groups for overall (OS) and progression-free
  survival (PFS). However, survival prediction based mainly on metabolites obtained
  from biofluids remains elusive.</p> </span> <span class="a-plus-plus abstract-section
  id-a-sec2"> <h3 class="a-plus-plus">Objectives</h3> <p class="a-plus-plus">This
  ...'
---
 <h3 class="a-plus-plus">Abstract</h3> <span class="a-plus-plus abstract-section id-a-sec1"> <h3 class="a-plus-plus">Introduction</h3> <p class="a-plus-plus">Metabolomics has emerged as a powerful method to provide insight into cancer progression, including separating patients into low- and high-risk groups for overall (OS) and progression-free survival (PFS). However, survival prediction based mainly on metabolites obtained from biofluids remains elusive.</p> </span> <span class="a-plus-plus abstract-section id-a-sec2"> <h3 class="a-plus-plus">Objectives</h3> <p class="a-plus-plus">This ...